Enveric Biosciences Completes $5 Million Public Offering Enveric Biosciences a leading biotechnology company focused on the development of groundbreaking neuroplastogenic small-molecule therapeutics, has made a significant advancement in its efforts to address some of the most pressing challenges in mental…
AdvanCell Closes Oversubscribed $112M Series C Funding AdvanCell, a pioneering clinical-stage radiopharmaceutical company focused on developing groundbreaking cancer therapeutics, has announced the successful closure of an oversubscribed US$112 million Series C financing round. This significant milestone highlights the confidence investors…
Sionna Therapeutics Announces $150M IPO to Advance Cystic Fibrosis Drug Development Sionna Therapeutics, a Massachusetts-based biotechnology company specializing in cystic fibrosis (CF) treatments, has officially announced the terms of its highly anticipated initial public offering (IPO). The company aims to…
Galderma’s Breakthrough Findings Galderma (SWX:GALD), a global leader in dermatology, has announced the results of its Phase IIIb RELAX clinical trial, demonstrating the rapid onset, long-lasting efficacy, and high patient satisfaction of RelabotulinumtoxinA (Relfydess™) for treating frown lines (glabellar lines).…
KORU Medical Systems Partners on Phase III Trial for Rare Renal Disorder Treatment, Expanding Its Reach in Subcutaneous Infusion Solutions KORU Medical Systems (NASDAQ: KRMD), a leading innovator in large-volume subcutaneous infusion solutions, has announced an exciting collaboration with a…
Ferrer Achieves Compliance Leader Verification™: A Testament to Excellence in Ethics and Corporate Responsibility In a significant milestone for ethical business practices, Ferrer, a global pharmaceutical company headquartered in Barcelona, has been awarded the prestigious Compliance Leader Verification™ by Ethisphere,…
Lead Capital Partners and Petra Capital Partners Propel Lieberman’s Growth with Strategic Platform Investment In a landmark move set to bolster its position as a leader in primary market research, Lieberman, Inc., a premier research and analytics firm, has secured…
PFID Poll: Bipartisan Support for Continued Vaccine Availability and Concern Over Declining Childhood Vaccination Rates The Partnership to Fight Infectious Disease (PFID) has released the results of a public opinion poll that highlights a strong consensus among American voters on…
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to developing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other severe conditions driven by protein growth factors, has officially submitted a Biologics License Application (BLA) to the U.S.…
JCR Pharmaceuticals to Present at the 21st Annual WORLDSymposium™ 2025 in San Diego JCR Pharmaceuticals Co., Ltd. (TSE 4552), a leading global specialty pharmaceutical company, has announced its participation in the 21st Annual WORLDSymposium™ 2025, which will take place from…
GeminiBio Appoints Matt Stober to Board of Directors Gemini Bioproducts, LLC (“GeminiBio”), a leading supplier of raw materials to the biopharmaceutical and advanced therapy industries, has announced the appointment of Matthew Stober to its Board of Directors. This strategic addition…
Sage Therapeutics Explores Strategic Alternatives and Rejects Biogen’s Acquisition Offer Sage Therapeutics, Inc. (Nasdaq: SAGE), a leader in brain health therapeutics, announced today that its Board of Directors has initiated a formal process to explore strategic alternatives for the company.…